美國支持豁免對新冠疫苗知識產權保護 開拓/國藥/康希諾/復星醫藥急挫11%-22%
美國總統拜登表示,將支持世界貿易組織的一項提議,即豁免對新冠疫苗知識產權保護,以幫助加快全球生產。市場預計消息不利疫苗股。
於本港上市疫苗股以復星醫藥(02196.HK)表現最差,股價由紀錄高位掉頭三連吐,尤其是今早股價失守10天線(47.8元)後,沽盤持續湧現,最低見41.7元喘定,現造43.6元,急挫逾22%,但20天線(42.1元)失而復得,成交急增至4,375萬股,為近幾年罕見。
康希諾生物-B(06185.HK)四連跌,尤其是今早股價一舉跌破50天、20天及50天線(318.9-359.2元),現造286元即市低位,急挫近22%,成交增至365萬股。
國藥(01099.HK)也跌破10天及20天線(24.4元及23.3元),最低見21.85元,現造22.5元,挫近13%,成交增至2,391萬股。開拓藥業-B(09939.HK)由收市紀錄高位三連跌,今天股價失守10天線(66.65元),最低見58.1元,現造62.3元,續挫11%,成交增至319萬股
藍籌中生製藥(01177.HK)一舉失守5條移動平均線(7.8-8.4元),報7.76元,續跌7.6%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.